Swiss biotech CDR-Life returns to Boehringer Ingelheim to partner on autoimmune T cell engagernews2025-11-04T13:00:32+00:00November 4th, 2025|Endpoints News|
Blackstone to pay Merck $700M to fund development of antibody-drug conjugatenews2025-11-04T12:29:04+00:00November 4th, 2025|Endpoints News|
Pfizer trims pipeline, reports 7% revenue decline for Q3news2025-11-04T12:07:42+00:00November 4th, 2025|Endpoints News|
South Korean biotech sets up California startup to advance ADCsnews2025-11-04T12:00:25+00:00November 4th, 2025|Endpoints News|
Post-Hoc Live: M&A, FDA, MFN and more — with our cousins at the FTnews2025-11-04T12:00:13+00:00November 4th, 2025|Endpoints News|
Compass plots quicker path to approval, launch readiness for depression drugnews2025-11-04T11:46:13+00:00November 4th, 2025|Endpoints News|
Nuvation Bio backs off from head-to-head brain cancer trialnews2025-11-04T10:33:54+00:00November 4th, 2025|Endpoints News|
Duchenne confirmatory trial fails, but Sarepta to ask FDA for full approval anywaysnews2025-11-04T00:20:06+00:00November 4th, 2025|Endpoints News|
Day after resigning, Tidmarsh now says he’ll fight exit from FDAnews2025-11-03T20:55:14+00:00November 3rd, 2025|Endpoints News|
AbbVie gets early win in Oklahoma 340B fight, but faces setback in Coloradonews2025-11-03T20:18:49+00:00November 3rd, 2025|Endpoints News|
